Rebecca A. Carter

Rebecca A. Carter is an attorney specializing in complex patent litigation, with a notable focus on pharmaceutical and biotechnology disputes. Her experience primarily involves representing innovator companies in actions concerning the Biologics Price Competition and Innovation Act (BPCIA) and biosimilar challenges.

Ms. Carter's practice has predominantly been on the plaintiff side, representing patent holders in enforcing their intellectual property rights. All tracked appearances show her representing plaintiffs, including a leading pharmaceutical company in cases against biosimilar manufacturers.

Currently a Senior Associate at Clinton & Peed, Ms. Carter previously practiced at Williams & Connolly LLP, where her significant patent litigation experience was gained. Before that, she also worked at Winston & Strawn.

Her representative patent litigation matters include her involvement as counsel for Regeneron Pharmaceuticals, Inc. in its cases against biosimilar developers. She served as Counsel in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al. (N.D. W. Va.), a BPCIA dispute involving patents protecting Regeneron's EYLEA® (aflibercept). She also acted as Lead Counsel for Regeneron Pharmaceuticals, Inc. in Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc. (N.D. W. Va.), another significant biosimilar patent battle concerning 38 patents related to EYLEA®, which was eventually dismissed without prejudice. No specific information regarding her involvement in PTAB or IPR proceedings is readily available.

Ms. Carter earned her Juris Doctor from UCLA School of Law and holds a Bachelor of Arts in Philosophy and Psychology from the University of Miami. She is admitted to practice in the District of Columbia, Illinois, and Maryland, as well as several federal courts, including the U.S. District Court for the Northern District of Illinois, the U.S. District Court for the District of Maryland, and the U.S. Court of Appeals for the Fifth Circuit.